ASX:RSH

Stock Analysis Report

Executive Summary

Respiri Limited, a health technology company, researches, develops, and commercializes, medical devices in Australia and Israel.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Respiri's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RSH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

RSH

4.4%

AU Medical Equipment

0.3%

AU Market


1 Year Return

-7.5%

RSH

-1.3%

AU Medical Equipment

-22.9%

AU Market

Return vs Industry: RSH underperformed the Australian Medical Equipment industry which returned -1.3% over the past year.

Return vs Market: RSH exceeded the Australian Market which returned -22.9% over the past year.


Shareholder returns

RSHIndustryMarket
7 Day0%4.4%0.3%
30 Day8.8%-23.2%-27.8%
90 Day-19.6%-26.9%-30.0%
1 Year-7.5%-7.5%0.4%-1.3%-19.4%-22.9%
3 Year76.2%76.2%18.2%12.7%-8.3%-20.8%
5 Year-22.1%-23.7%56.9%43.2%2.9%-20.3%

Price Volatility Vs. Market

How volatile is Respiri's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Respiri undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Respiri is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Respiri has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of RSH’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Respiri regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Respiri forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

40.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Respiri performed over the past 5 years?

-5.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RSH is currently unprofitable.

Growing Profit Margin: RSH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RSH is unprofitable, and losses have increased over the past 5 years at a rate of -5.4% per year.

Accelerating Growth: Unable to compare RSH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RSH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).


Return on Equity

High ROE: RSH's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Respiri's financial position?


Financial Position Analysis

Short Term Liabilities: RSH has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: RSH has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: RSH has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: RSH's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: RSH has a low level of unsold assets or inventory.

Debt Coverage by Assets: RSH has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RSH has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RSH has less than a year of cash runway if free cash flow continues to grow at historical rates of 13.2% each year.


Next Steps

Dividend

What is Respiri's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RSH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RSH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RSH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RSH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Marjan Mikel

0.25

Tenure

Mr. Marjan Mikel (M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer since December 02, 2019 and serves as Director since November 25, 2019. He served as an Independent Non-Executive Dire ...


Leadership Team

NamePositionTenureCompensationOwnership
Koswani Wall
Chief Customer Experience & Communications Officer1.75yrsAU$257.44k0.065% A$28.3k
Samaneh Shirazi
Chief Research Officer1yrAU$327.89kno data
Nicholas Smedley
Executive Chairman0.33yrno data1.31% A$573.3k
Marjan Mikel
Former Director0.25yrno data0.15% A$65.0k
Jan Barker
Vice-President of Business Development8.17yrsno datano data
Alastair Beard
Company Secretary1yrno datano data
Noam Gavriely
Medical & Scientific Advisorno dataAU$310.61kno data
Simon Godfrey
Medical & Scientific Advisorno datano datano data

1.0yrs

Average Tenure

Experienced Management: RSH's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Nicholas Smedley
Executive Chairman0.33yrno data1.31% A$573.3k
Marjan Mikel
Former Director0.25yrno data0.15% A$65.0k
Thomas Duthy
Non-Executive Director0.083yrAU$4.17k0.036% A$15.8k
Bruce Thompson
Chairman of the Medical & Scientific Advisory Boardno dataAU$73.76kno data

0.3yrs

Average Tenure

Experienced Board: RSH's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RSH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.1%.


Top Shareholders

Company Information

Respiri Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Respiri Limited
  • Ticker: RSH
  • Exchange: ASX
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$43.854m
  • Shares outstanding: 592.62m
  • Website: https://www.respiri.co

Location

  • Respiri Limited
  • 101 Collins Street
  • Level 27
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RSHASX (Australian Securities Exchange)YesOrdinary SharesAUAUDNov 2006
KMLX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2006
RSHCHIA (Chi-X Australia)YesOrdinary SharesAUAUDNov 2006

Biography

Respiri Limited, a health technology company, researches, develops, and commercializes, medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include Wheezo, a mobile app, which has asthma management diary, medication usage and reminders, and symptoms and triggers to help asthma sufferers; Wholter, a device for home ambulatory recording of nocturnal wheeze and cough; and AirSonea, a digital stethoscope that is paired to a smartphone app to record breathing sounds accurately. The company also offers PulmoTrack, a computerized wheeze detection product designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute asthma in the ER and ICU, and for pediatric pulmonary function testing and sleep labs; and SonoSentry, an over-the-counter wheeze-detection device. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited was incorporated in 1987 and is based in Melbourne, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 10:35
End of Day Share Price2020/03/16 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.